Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. reduced its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 16.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 89,719 shares of the company’s stock after selling 17,697 shares during the quarter. Principal Financial Group Inc.’s holdings in Teva Pharmaceutical Industries were worth $1,617,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the business. Sanctuary Advisors LLC boosted its stake in Teva Pharmaceutical Industries by 1.9% during the 3rd quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company’s stock worth $601,000 after purchasing an additional 664 shares during the period. Sequoia Financial Advisors LLC boosted its stake in shares of Teva Pharmaceutical Industries by 0.7% during the third quarter. Sequoia Financial Advisors LLC now owns 112,380 shares of the company’s stock worth $2,025,000 after buying an additional 805 shares during the period. DGS Capital Management LLC grew its holdings in shares of Teva Pharmaceutical Industries by 6.8% during the third quarter. DGS Capital Management LLC now owns 13,627 shares of the company’s stock worth $246,000 after buying an additional 872 shares during the last quarter. Smithfield Trust Co increased its position in Teva Pharmaceutical Industries by 55.7% in the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock valued at $50,000 after acquiring an additional 980 shares during the period. Finally, Signaturefd LLC raised its stake in Teva Pharmaceutical Industries by 16.9% during the 3rd quarter. Signaturefd LLC now owns 7,583 shares of the company’s stock valued at $137,000 after acquiring an additional 1,094 shares during the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on TEVA shares. StockNews.com downgraded Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Barclays boosted their price objective on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the company an “overweight” rating in a research note on Wednesday, December 18th. Finally, JPMorgan Chase & Co. raised their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, October 21st. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $20.88.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $21.24 on Friday. The stock has a market cap of $24.06 billion, a PE ratio of -24.99, a price-to-earnings-growth ratio of 0.99 and a beta of 0.73. Teva Pharmaceutical Industries Limited has a fifty-two week low of $10.75 and a fifty-two week high of $22.80. The firm’s fifty day simple moving average is $18.60 and its 200-day simple moving average is $17.87. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, Director Roberto Mignone sold 286,000 shares of the stock in a transaction on Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the sale, the director now owns 695,000 shares of the company’s stock, valued at $15,296,950. This trade represents a 29.15 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total transaction of $327,075.56. Following the sale, the executive vice president now owns 44,104 shares of the company’s stock, valued at approximately $744,034.48. This trade represents a 30.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.55% of the stock is currently owned by corporate insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.